Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4066536 | 0.92 | DUT (0.52) | DUTKMT2A | |
| SCHEMBL17889263 | 0.82 | DUT (0.38) | DUTDGAT1MEN1KMT2A | |
| SCHEMBL17889261 | 0.82 | DUT (0.38) | DUTDGAT1MEN1KMT2A | |
| SCHEMBL21517829 | 0.79 | DUT (0.36) | DUTDGAT1 | |
| SCHEMBL2796845 | 0.79 | ALDH1A1 (0.49) | DUTKMT2A | |
| SCHEMBL4760928 | 0.79 | KMT2A (0.37) | MEN1KMT2A | |
| SCHEMBL17897627 | 0.78 | NPC1 (0.35) | DUTDGAT1 | |
| SCHEMBL11925813 | 0.78 | DUT (0.42) | DUTKMT2A | |
| SCHEMBL24849041 | 0.77 | FDPS (0.30) | — | |
| SCHEMBL21167268 | 0.76 | MEN1 (0.30) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511002-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| EP-3050877-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| WO-2015046403-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 | 2015-04-02 | — | — | WO | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | DUT 462/4885DGAT1 4349/4885MEN1 219/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | DUT 602/4885DGAT1 4300/4885MEN1 2888/4885 |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, OPRL1, CNR1 | DUT 2317/4885DGAT1 4399/4885MEN1 1784/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | DUT 813/4885DGAT1 4741/4885MEN1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.